{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:20:27Z","timestamp":1761895227053},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T00:00:00Z","timestamp":1295827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T00:00:00Z","timestamp":1295827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1038\/bmt.2010.339","type":"journal-article","created":{"date-parts":[[2011,1,24]],"date-time":"2011-01-24T11:52:06Z","timestamp":1295869926000},"page":"1503-1509","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["90Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma"],"prefix":"10.1038","volume":"46","author":[{"given":"K E","family":"Abou-Nassar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K E","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Antin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V T","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C S","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E D","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Soiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E P","family":"Alyea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A S","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,24]]},"reference":[{"key":"BFbmt2010339_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/asheducation-2006.1.303","volume":"1","author":"MS Czuczman","year":"2006","unstructured":"Czuczman MS . Controversies in follicular lymphoma: \u2018who, what, when, where, and why?\u2019 (not necessarily in that order!). Hematol Am Soc Hematol Educ Program 2006; 1: 303\u2013310.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"BFbmt2010339_CR2","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","volume":"17","author":"E Gin\u00e9","year":"2006","unstructured":"Gin\u00e9 E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict transformation in follicular lymphoma. Ann Oncol 2006; 17: 1539\u20131545.","journal-title":"Ann Oncol"},{"key":"BFbmt2010339_CR3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.bbmt.2007.05.012","volume":"13","author":"JR Brown","year":"2007","unstructured":"Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13: 1057\u20131065.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010339_CR4","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.bbmt.2007.04.009","volume":"13","author":"M Sabloff","year":"2007","unstructured":"Sabloff M, Atkins HL, Bence-Bruckler I, Bredeson C, Fergusson D, Genest P et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007; 13: 956\u2013964.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010339_CR5","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR6","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595\u20133599.","journal-title":"Blood"},{"key":"BFbmt2010339_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236\u2013245.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010339_CR8","first-page":"386","volume":"2","author":"MV Peters","year":"1975","unstructured":"Peters MV, Busch RS, Brown TC, Reid J . The place of radiotherapy in the control on non-Hodgkin's lymphomata. Br J Cancer 1975; 2: 386\u2013401.","journal-title":"Br J Cancer"},{"key":"BFbmt2010339_CR9","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","volume":"103","author":"LI Gordon","year":"2004","unstructured":"Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study. Blood 2004; 103: 4429\u20134431.","journal-title":"Blood"},{"key":"BFbmt2010339_CR10","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","volume":"10","author":"TA Davis","year":"2004","unstructured":"Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10: 7792\u20137798.","journal-title":"Clin Cancer Res"},{"key":"BFbmt2010339_CR11","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336\u20134342.","journal-title":"Blood"},{"key":"BFbmt2010339_CR12","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262\u20133269.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804\u20131810.","journal-title":"Cancer"},{"key":"BFbmt2010339_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1089\/cbr.2007.359","volume":"22","author":"C Emmanouilides","year":"2007","unstructured":"Emmanouilides C, Witzig TE, Wiseman GA, Gordon LI, Wang H, Schilder R et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007; 22: 684\u2013691.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFbmt2010339_CR15","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","volume":"114","author":"JM Pagel","year":"2009","unstructured":"Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM et al. Allogeneic hematopoietic-cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114: 5444\u20135453.","journal-title":"Blood"},{"key":"BFbmt2010339_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/10428190500260478","volume":"47","author":"T Fietz","year":"2006","unstructured":"Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47: 59\u201363.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2010339_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bmt.1705919","volume":"41","author":"A Shimoni","year":"2008","unstructured":"Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 2008; 41: 355\u2013361.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010339_CR18","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","volume":"14","author":"P Armand","year":"2008","unstructured":"Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14: 418\u2013425.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010339_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.bbmt.2008.05.024","volume":"14","author":"EP Alyea","year":"2008","unstructured":"Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008; 14: 920\u2013926.","journal-title":"Biol Blood Marrow Transplant."},{"key":"BFbmt2010339_CR20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.bbmt.2009.03.017","volume":"15","author":"VT Ho","year":"2009","unstructured":"Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P et al. Comparison of tacrolimus and sirolimus (Tac\/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac\/Sir\/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 844\u2013850.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2010339_CR21","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2010339_CR22","doi-asserted-by":"publisher","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156\u20135164.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR23","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565\u20137573.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","volume":"35","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534\u2013540.","journal-title":"Exp Hematol"},{"key":"BFbmt2010339_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","volume":"23","author":"JM Vose","year":"2005","unstructured":"Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461\u2013467.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR26","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","volume":"116","author":"WA Bethge","year":"2010","unstructured":"Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase II study. Blood 2010; 116: 1795\u20131802.","journal-title":"Blood"},{"key":"BFbmt2010339_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2032s lymphoma. J Clin Oncol 2008; 26: 211\u2013217.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1365-2141.2009.07674.x","volume":"145","author":"V Ratanatharathorn","year":"2009","unstructured":"Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816\u2013824.","journal-title":"Br J Haematol"},{"key":"BFbmt2010339_CR29","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1200\/JCO.2008.17.7279","volume":"26","author":"P Armand","year":"2008","unstructured":"Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26: 5767\u20135774.","journal-title":"J Clin Oncol"},{"key":"BFbmt2010339_CR30","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","volume":"100","author":"SP Robinson","year":"2002","unstructured":"Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310\u20134316.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2010339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010339","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2010339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T13:34:28Z","timestamp":1648042468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2010339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,24]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["BFbmt2010339"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.339","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,24]]},"assertion":[{"value":"27 August 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}